Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MIRA Mira Pharma

Pre-Mkt 10-09 07:39:37 EDT

0.7030

-0.0070

-0.99%

High0.7100	Low0.6805	Vol142.66K
Open0.7100	D1 Closing0.7100	Amplitude4.15%
Mkt Cap29.44M	Tradable Cap24.57M	Total Shares41.88M
T/O99.52K	T/O Rate0.41%	Tradable Shares34.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":0.703,"timestamp":1791489600000,"preClose":0.71,"halted":0,"volume":142664,"delay":0,"changeRate":-0.009859154929577474,"floatShares":34944200,"shares":41876087,"eps":-1.3802,"marketStatus":"Pre-Mkt","change":-0.007,"latestTime":"10-09 07:39:37 EDT","open":0.71,"high":0.71,"low":0.6805,"amount":99515.46864968,"amplitude":0.041549,"askPrice":0.8358,"askSize":100,"bidPrice":0.66,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.3802,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":0.703,"postHourTrading":{"tag":"盘后","latestPrice":0.703,"preClose":0.703,"latestTime":"19:30 EDT","volume":183,"amount":128.649,"timestamp":1791502203517,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6546880985776364},"requestUrl":"/m/hq/s/MIRA","defaultTab":"news","newsList":[{"id":"2668995601","title":"MIRA Pharmaceuticals Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2668995601","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668995601?lang=en_us&edition=fundamental","pubTime":"2026-09-17 23:19","pubTimestamp":1789658340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MIRA/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668967482","title":"MIRA advances Ketamir-2 Phase 2a neuropathy program","url":"https://stock-news.laohu8.com/highlight/detail?id=2668967482","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668967482?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:58","pubTimestamp":1789649919,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. On Sept. 17, 2026, MIRA Pharmaceuticals announced that its Phase 2a clinical program...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-advances-ketamir-2-phase-2a-neuropathy-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-advances-ketamir-2-phase-2a-neuropathy-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668671649","title":"Mira advances Ketamir-2 to chemotherapy-induced peripheral neuropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2668671649","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668671649?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:45","pubTimestamp":1789649153,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (MIRA) announced that, following review and comments from the FDA, the Phase 2a protocol evaluating Ketamir-2 in chemotherapy-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-advances-ketamir-2-to-chemotherapy-induced-peripheral-neuropathy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-advances-ketamir-2-to-chemotherapy-induced-peripheral-neuropathy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MIRA","LABU","BK4588","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668296214","title":"MIRA Pharmaceuticals Submits Ketamir-2 Phase 2a CIPN Protocol for IRB Review After FDA Feedback","url":"https://stock-news.laohu8.com/highlight/detail?id=2668296214","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668296214?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:32","pubTimestamp":1789648350,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals submits Ketamir-2 Phase 2a CIPN protocol for IRB review after FDA feedbackMira Pharmaceuticals submitted a Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL3JzwKz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00BN0W2V16.EUR","IE00BQXX3D17.EUR","BK4007","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014005.SGD","BK4588","SG9999014021.USD","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","MIRA","BK4585","LU2095319765.USD","BK4112","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014013.SGD","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","NDAQ","IE00BQXX3F31.USD","LU2210149790.SGD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668962936","title":"Mira Pharmaceuticals - Targets Site Initiation for Phase 2a Ketamir-2 Study in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2668962936","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668962936?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:30","pubTimestamp":1789648202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA1NCPJC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668962671","title":"Mira Pharmaceuticals - Submits Phase 2a Protocol for Ketamir-2 in Cipn to Irb After FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2668962671","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668962671?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:30","pubTimestamp":1789648202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA1NCPJC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668629399","title":"Mira Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (Cipn) Following FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2668629399","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668629399?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:30","pubTimestamp":1789648202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA1NCPJC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668964179","title":"Mira Pharmaceuticals initiated with a Buy at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2668964179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668964179?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:50","pubTimestamp":1789645815,"startTime":"0","endTime":"0","summary":"Maxim analyst Jason McCarthy initiated coverage of Mira Pharmaceuticals (MIRA) with a Buy rating and $3.50 price target Published first on TheFly –...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-initiated-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-initiated-with-a-buy-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668961072","title":"Mira Pharmaceuticals Inc : Maxim Group Initiates Coverage with Buy Rating; Target Price $3.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2668961072","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668961072?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:49","pubTimestamp":1789645750,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nFWN4590KT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668954985","title":"U.S. Research Roundup-Celcuity, Fluence Energy, Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2668954985","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668954985?lang=en_us&edition=fundamental","pubTime":"2026-09-17 15:11","pubTimestamp":1789629115,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, SalesforceSept 17 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Celcuity","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4N4590IX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HBAN","MNRS","LFGY","IBIO","FLNC","APLD","MAA","BSX","CRCL","CIEN","CELC","ATRC","CRGY","JEF","MIRA","STZ","HUBG","IOVA","DOW","CRK","TKNO","BKCH","SPAM","CORZ","GCPU","AUGO","CIFR","ELF","BITQ","IGV","HUT","HAKY","CRWD","KOPN","STCE","FTNT","ENVA","APLX","CHRD","NETL","SPRE","JBHT","ADC","CRL","CLOU","NET","MCD","HAE","MGNI","BMRN","ALHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668358779","title":"Mira Pharmaceuticals Holds Annual Shareholder Meeting with 63.06% of Shares Represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2668358779","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668358779?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:33","pubTimestamp":1789590828,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals holds annual shareholder meeting with 63.06% of shares representedMira Pharmaceuticals held its 2026 annual shareholder meeting on Sept. 11, 2026.Shareholders backed the board’s s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL4kfwkH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664567498","title":"Mira Pharmaceuticals - Targets Ind Application Submission for Mira-55 to FDA in Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2664567498","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664567498?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:07","pubTimestamp":1788264464,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nFWN44T0HM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664215856","title":"MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND","url":"https://stock-news.laohu8.com/highlight/detail?id=2664215856","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664215856?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"Positive Toxicology Results From 7-Day Rat and Dog Studies Characterize Tolerability and Inform Dose Selection for Next Phase of IND-Enabling Program, Targeting Q1 2027 IND SubmissionMIAMI, Sept.  01,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354093/0/en/mira-pharmaceuticals-advances-non-opioid-oral-mira-55-for-inflammatory-pain-toward-ind.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IND","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659007929","title":"Mira Pharmaceuticals Q2 2026 Net Loss Narrows to $1.21 Million; Revenue Remains no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659007929","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659007929?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:27","pubTimestamp":1786566434,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Q2 2026 net loss narrows to $1.21 million; revenue remains no revenueMira Pharmaceuticals posted a net loss of USD 1.21 million for the quarter ended June 30, 2026, narrowing from","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL9DyBgG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657636112","title":"Mira Pharma Reports Positive 7-Day Dog Toxicokinetic Study Results for Obesity Drug Candidate SKNY-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657636112","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657636112?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:02","pubTimestamp":1786017749,"startTime":"0","endTime":"0","summary":"Mira Pharma reports positive 7-day dog toxicokinetic study results for obesity drug candidate SKNY-1Mira Pharmaceuticals reported positive results from a 7-day repeated-dose Beagle dog study of SKNY-1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3Ftx0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656946683","title":"MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2656946683","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656946683?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:33","pubTimestamp":1785533612,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. On July 27, 2026, MIRA Pharmaceuticals received notice from Nasdaq that its common s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mira-pharmaceuticals-receives-nasdaq-minimum-bid-price-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCLG","BK4007","MIRA","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656391125","title":"Mira Pharmaceuticals Risks NASDAQ Delisting After Shares Fall Below $1 Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2656391125","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656391125?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:01","pubTimestamp":1785531668,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals risks Nasdaq delisting after shares fall below $1 bid price requirementMira Pharmaceuticals received a Nasdaq notice for failing to meet the $1 minimum bid price rule after 30 str","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL8blR1c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655080351","title":"Mira Pharmaceuticals provides update on MIRA-55, SKNY-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2655080351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655080351?lang=en_us&edition=fundamental","pubTime":"2026-07-30 21:36","pubTimestamp":1785418597,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals (MIRA) announced continued advancement of its two preclinical programs, MIRA-55, an investigational oral non-opioid drug candi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-provides-update-on-mira-55-skny-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mira-pharmaceuticals-provides-update-on-mira-55-skny-1-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MIRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655872999","title":"Mira Pharmaceuticals Advances Mira-55 Toward IND-enabling Studies After Completing Exploratory Tox Dosing in Rats, Dogs","url":"https://stock-news.laohu8.com/highlight/detail?id=2655872999","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655872999?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:08","pubTimestamp":1785413331,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals advances MIRA-55 toward IND-enabling studies after completing exploratory tox dosing in rats, dogsMira Pharmaceuticals moved two preclinical oral candidates, MIRA-55 for chronic i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL3wHQ9G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","SG9999014005.SGD","MIRA","NDAQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","BCDF","LU2210150020.SGD","BK4007","BK4585","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","SG9999014039.USD","BK4588","IE00BN0W2W23.USD","SG9999014021.USD","LU2210149790.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655687216","title":"MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2655687216","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655687216?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:00","pubTimestamp":1785412800,"startTime":"0","endTime":"0","summary":"Completion of 7-Day Toxicology and Pharmacokinetic Studies Advances Non-Opioid Pain Therapy and Obesity Candidate DevelopmentMIAMI, July  30, 2026  (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASD","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/30/3335999/0/en/MIRA-Pharmaceuticals-Progresses-MIRA-55-and-SKNY-1-Toward-IND-Enabling-Studies.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","BK4194","LU0267386448.USD","LU0170899867.USD","LU2746668461.USD","IE00BKVL7J92.USD","LU0971096721.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","BK4223","MIRA","LU2746668974.SGD","LU2237443978.SGD","LU2237443382.USD","LU2237443622.USD","LU2237443549.SGD","IND","IE00B1BXHZ80.USD","LU2237443465.HKD","BK4006","DEA","BK4007","CMC","LU2237443895.HKD","IE00BHPRN162.USD","IE00BFXG1179.USD","LU0149725797.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mirapharmaceuticals.com","stockEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0938},{"period":"3month","weight":-0.2396},{"period":"6month","weight":-0.2945},{"period":"1year","weight":-0.4674},{"period":"ytd","weight":-0.5344}],"compareEarnings":[{"period":"1week","weight":0.013},{"period":"1month","weight":0.0104},{"period":"3month","weight":0.0251},{"period":"6month","weight":0.139},{"period":"1year","weight":0.1498},{"period":"ytd","weight":0.1349}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.076979},{"month":2,"riseRate":0.666667,"avgChangeRate":-0.024441},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.027651},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.020794},{"month":5,"riseRate":0.666667,"avgChangeRate":0.045339},{"month":6,"riseRate":0,"avgChangeRate":-0.14408},{"month":7,"riseRate":0.666667,"avgChangeRate":0.832369},{"month":8,"riseRate":0,"avgChangeRate":-0.092725},{"month":9,"riseRate":0.25,"avgChangeRate":-0.123916},{"month":10,"riseRate":0.5,"avgChangeRate":0.040477},{"month":11,"riseRate":0.333333,"avgChangeRate":0.101722},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.266745}],"exchange":"NASDAQ","name":"Mira Pharma","nameEN":"Mira Pharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Mira Pharma,MIRA,Mira Pharma股票,Mira Pharma股票老虎,Mira Pharma股票老虎国际,Mira Pharma行情,Mira Pharma股票行情,Mira Pharma股价,Mira Pharma股市,Mira Pharma股票价格,Mira Pharma股票交易,Mira Pharma股票购买,Mira Pharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Mira Pharma(MIRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Mira Pharma(MIRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}